Tolerability and Efficacy of RJX in Patients With COVID-19

Clinical trial NCT04708340 · UNKNOWN

Trial details

NCT number: NCT04708340
Sponsor: Reven Pharmaceuticals, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

COVID-19 Acute Respiratory Distress Syndrome SARS-CoV-2 Hypoxemia

Start date: 2021-03-25
Primary completion: 2022-10-01
Enrollment: 237

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.